Race, poverty, and initial implementation of precision medicine for lung cancer
KL Kehl, CS Lathan, BE Johnson… - JNCI: Journal of the …, 2019 - academic.oup.com
Data are limited regarding whether the availability of biomarker-directed therapy for lung
cancer exacerbates racial and socioeconomic disparities. Patients diagnosed with stage IV …
cancer exacerbates racial and socioeconomic disparities. Patients diagnosed with stage IV …
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
LC Villaruz, MA Socinski, J Weiss - Frontiers in Oncology, 2023 - frontiersin.org
Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have
resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the …
resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the …
[HTML][HTML] Ultrarapid EGFR mutation screening followed by comprehensive next-generation sequencing: a feasible, informative approach for lung carcinoma cytology …
Introduction For patients with advanced NSCLC, cytologic samples may be the only
diagnostic specimen available for molecular profiling. Although both rapid and …
diagnostic specimen available for molecular profiling. Although both rapid and …
[HTML][HTML] Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns …
L Paz-Ares, A Gondos, D Saldana, M Thomas… - Lung Cancer, 2022 - Elsevier
Abstract Objectives According to 2018 United States and international lung cancer and
pathology guidelines, testing of EGFR, ALK, ROS1 and BRAF genes is a minimum …
pathology guidelines, testing of EGFR, ALK, ROS1 and BRAF genes is a minimum …
Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice
Plasma-based next-generation sequencing (NGS) has demonstrated the potential to guide
the personalized treatment of non-small cell lung cancer (NSCLC). Inherent differences in …
the personalized treatment of non-small cell lung cancer (NSCLC). Inherent differences in …
Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective
U Malapelle, M Tiseo, A Vivancos, J Kapp… - Journal of Molecular …, 2021 - mdpi.com
The development of targeted therapies has improved survival rates for patients with
advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or …
advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or …
A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer
W Cui, C Milner-Watts, TP McVeigh, A Minchom… - Lung Cancer, 2022 - Elsevier
Introduction The diagnostic pathway for lung cancer can be long. Availability of front-line
targeted therapies for NSCLC demands access to good quality tissue for genomic …
targeted therapies for NSCLC demands access to good quality tissue for genomic …
[HTML][HTML] Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-Care tissue testing in advanced non–small cell lung cancer
RD Page, LM Drusbosky, H Dada, VM Raymond… - Clinical lung cancer, 2022 - Elsevier
Background: Somatic genomic testing is recommended by numerous expert guidelines to
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …
[HTML][HTML] Sociodemographic disparities in the management of advanced lung cancer: a narrative review
JN Stein, MP Rivera, A Weiner, N Duma… - Journal of thoracic …, 2021 - ncbi.nlm.nih.gov
Abstract Treatment of advanced non-small cell lung cancer (NSCLC) has markedly changed
in the past decade with the integration of biomarker testing, targeted therapies …
in the past decade with the integration of biomarker testing, targeted therapies …
Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study
B Gardner, M Doose, JI Sanchez… - JCO Precision …, 2021 - ascopubs.org
PURPOSE Oncologists are increasingly using molecular profiling to inform personalized
patient treatment decisions. Despite its promising utility, the integration of genomic testing …
patient treatment decisions. Despite its promising utility, the integration of genomic testing …